Hostname: page-component-788cddb947-rnj55 Total loading time: 0 Render date: 2024-10-11T19:28:16.623Z Has data issue: false hasContentIssue false

Clinical Epidemiology of Ciprofloxacin Resistance and Its Relationship to Broad-Spectrum Cephalosporin Resistance in Bloodstream Infections Caused by Enterobacter Species

Published online by Cambridge University Press:  21 June 2016

Cheol-In Kang
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Sung-Han Kim
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Wan Beom Park
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Ki-Deok Lee
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Hong-Bin Kim
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Eui-Chong Kim
Affiliation:
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea Clinical Research Institute, Seoul National University Hospital, Seoul, Korea
Myoung-don Oh*
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Clinical Research Institute, Seoul National University Hospital, Seoul, Korea
Kang-Won Choe
Affiliation:
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
*
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong Chongno-gu, Seoul 110-744, Republic of Koreamdohmd@snu.ac.kr

Abstract

Objectives:

To evaluate the clinical features of ciprofloxacin-resistant Enterobacter bacteremia and to examine the risk factors for ciprofloxacin resistance in Enterobacter species isolates causing bacteremia.

Design:

A case-control study.

Setting:

A 1,500-bed, tertiary-care university hospital and referral center.

Patients:

All patients older than 16 years with Enterobacter species isolated from blood were enrolled. The medical records of 183 patients with clinically significant Enterobacter bacteremia from January 1998 to December 2002 were identified. We compared patients with bacteremia caused by ciprofloxacin-susceptible isolates with patients with bacteremia caused by ciprofloxacin-resistant isolates.

Results:

Twenty-three (12.6%) of the patients had bacteremia caused by isolates resistant to ciprofloxacin. There were no significant differences in age, gender, underlying diseases, primary site of infection, or Acute Physiology and Chronic Health Evaluation II score between the ciprofloxacin-resistant and the ciprofloxacin-susceptible groups. Broad-spectrum cephalosporin resistance, defined as resistance to cefotaxime or ceftazidime in vitro, was detected in 21 (91.3%) of 23 ciprofloxacin-resistant isolates compared with 65 (40.6%) of 160 ciprofloxacin-susceptible isolates (P < .001). Multivariate analysis revealed that independent risk factors for ciprofloxacin resistance were the prior receipt of fluoroquinolones (P < .001) and broad-spectrum cephalosporin resistance (P < .001).

Conclusions:

In Enterobacter species isolates causing bacteremia, ciprofloxacin resistance was closely associated with the prior receipt of fluoroquinolones and broad-spectrum cephalosporin resistance. The close relationship between ciprofloxacin resistance and broad-spectrum cephalosporin resistance is particularly troublesome because it severely restricts the therapeutic options for Enterobacter species infection.

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Eisenstein, BI, Zaleznik, DEEnterobacteriaceae. In: Mandeli, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases, ed. 5. Philadelphia: Churchill Livingstone; 2000:22942310.Google Scholar
2.Watanakunakorn, C, Weber, J. Enterobacter bacteremia: a review of 58 episodes. Scand J Infect Dis 1989;21:18.CrossRefGoogle ScholarPubMed
3.Chow, JW, Fine, MJ, Shlaes, DM, et al.Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585590.CrossRefGoogle ScholarPubMed
4.Cosgrove, SE, Kaye, KS, Eliopoulous, GM, Carmeli, Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185190.CrossRefGoogle ScholarPubMed
5.Kaye, KS, Cosgrove, S, Harris, A, Eliopoulos, GM, Carmeli, Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001;45:26282630.CrossRefGoogle ScholarPubMed
6.Kang, CI, Kim, SH, Park, WB, et al.Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004;39:812818.CrossRefGoogle ScholarPubMed
7.Bouza, E, Cercenado, E. Klebsiella and Enterobacter, antibiotic resistance and treatment implications. Semin Respir Infect 2002;17:215230.CrossRefGoogle ScholarPubMed
8.Livermore, DM, James, D, Reacher, M, et al.Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias: England and Wales, 1990-1999. Emerg Infect Dis 2002;8:473478.CrossRefGoogle ScholarPubMed
9.Lautenbach, E, Fishman, NO, Bilker, WB, et al.Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:24692477.CrossRefGoogle ScholarPubMed
10.Paterson, DL, Mulazimoglu, L, Casellas, JM, et al.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473478.CrossRefGoogle ScholarPubMed
11.Kang, CI, Kim, SH, Kim, DM, et al.Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2004;10:7176.CrossRefGoogle ScholarPubMed
12.Jorgensen, JH, Turnidge, JD, Washington, JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology, ed. 7. Washington, DC: ASM Press; 1999:15261543.Google Scholar
13.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000. Approved standard M100-S12.Google Scholar
14.Knaus, WA, Drapier, EA, Wagner, DP, Zimmerman, JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818829.CrossRefGoogle ScholarPubMed
15.Garner, JS, Jarvis, WR, Emori, TG, et al.CDC definitions for nosocomial infections. Am f Infect Control 1988;16:128140.CrossRefGoogle ScholarPubMed
16.Kang, C-I, Kim, S-H, Kim, DM, et al.Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004;25:860867.CrossRefGoogle ScholarPubMed
17.Kang, CI, Kim, SH, Kim, HB, et al.Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745751.CrossRefGoogle Scholar
18.Pena, C, Albareda, JM, Pallares, R, et al.Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520524.CrossRefGoogle ScholarPubMed
19.Lautenbach, E, Strom, BL, Bilker, WB, Patel, JB, Edelstein, PH, Fishman, NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia colt and Klebsiella pneumoniae. Clin Infect Dis 2001;33:12881294.CrossRefGoogle Scholar
20.Tolun, V, Kucukbasmaci, O, Torumkuney-Akbulut, D, Catal, C, Angk-Kucuker, M, Ang, O. Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in Escherichia coli and Klebsiella pneumoniae strains. Clin Microbiol Infect 2004;10:7275.CrossRefGoogle ScholarPubMed
21.Harris, AD, Smith, D, Johnson, JA, Bradham, DD, Roghmann, MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002;34:340345.CrossRefGoogle ScholarPubMed
22.Ahmad, M, Urban, C, Mariano, N, et al.Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999;29:352355.CrossRefGoogle ScholarPubMed
23.Wang, M, Sahm, DF, Jacoby, GA, Hooper, DC. Emerging plasmid-medi-ated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004;48:12951299.CrossRefGoogle ScholarPubMed
24.Jacoby, GA, Chow, N, Waites, KB. Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003;47:559562.CrossRefGoogle ScholarPubMed
25.Deguchi, T, Yasuda, M, Nakano, M, et al.Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae. J Antimicrob Chemother 1997;40:543549.CrossRefGoogle ScholarPubMed
26.Kern, WY, Andriof, E, Oethinger, M, Kern, P, Hacker, J, Marre, R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681687.CrossRefGoogle Scholar
27.Yoo, JH, Huh, DH, Choi, JH, et al.Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis 1997;25:13851391.CrossRefGoogle ScholarPubMed
28.Harris, AD, Samore, MH, Lipsitch, M, Kaye, KS, Perencevich, E, Carmeli, Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002;34:15581563.CrossRefGoogle ScholarPubMed